Dr. Muhammad Amjad Mir, DO

Dr. Mir practices at E T Nephrology Associates PA in Lufkin, Texas.

Dr. Mir's NPI, 1912168501, was assigned on June 17, 2008. Dr. Mir graduated from New York Institute of Technology College of Osteopathic Medicine - Old Westbury in 2004. Dr. Mir holds Texas license N2667.

Dr. Mir's primary practice is E T Nephrology Associates PA, at 409 Gaslight Blvd, Lufkin, TX 75904 in Angelina County. The practice phone is (936) 634-2227.

Dr. Mir's primary practice is E T Nephrology Associates PA in Lufkin, Texas. Dr. Mir is also affiliated with St. Luke's Health - Memorial Hospital - Lufkin, TX. The medical group on file is East Texas Nephrology Associates. Dmand AI also links Dr. Mir to 4 more hospitals, 5 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mir practices, 11 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Mir's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Mir is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mir is licensed in Texas.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances and kidney cysts among the conditions Dr. Mir treats.

CMS data shows 1,911 Medicare services from Dr. Mir across 13 procedure codes in 2024, for 489 Medicare patients. Medicare paid $206,588 for them.

CMS counts 489 Medicare patients who saw Dr. Mir in 2024. The largest group is 75 to 84, with 161 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 26% are also on Medicaid. Their average risk score is 3.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mir's median patient age at 71, with 51% women.

In 2024, Dr. Mir wrote 851 Medicare Part D claims for 167 patients. 90% of them were for generic drugs. CMS names the drug for 619 of them, across 17 drugs with 11 or more claims each, at $18,807 in total drug cost. In 2023, CMS named 542 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Mir for performance year 2024, reported as part of a group. Dr. Mir accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Mir, published from 2014 to 2015. 2015 was the busiest year, with 4. The most frequent topics are Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation. Dr. Mir's most frequent co-authors are Divisha Raheja, MD, Luciano J. Costa and Amie Elissa Jackson, MD.

CMS Open Payments shows 117 general payments to Dr. Mir from 25 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $458.

Dmand AI lists 1 award for Dr. Mir, most recently CMS Stage 1 EHR in 2011.

Dr. Mir graduated from New York Institute of Technology College of Osteopathic Medicine - Old Westbury in 2004. Dr. Mir is a member of AOA, ASN and Renal Physician Association.

Dr. Mir is in network with 18 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.